Summary To determine whether resistance to chemoimmunotherapy is acquired during therapy, we investigated the effects of chemotherapeutic agents and anti-tumour polysaccharide, lentinan, on the progression of Rous sarcoma virus-induced S908.D2 fibrosarcomas. The chemoimmunotherapy was effective against the parental S908.D2-bearing mice. Nearly all the mice that were treated with cyclophosphamide (CY) and lentinan achieved complete tumour regression. Only a few of the mice that achieved complete regression of the primary tumours showed a recurrence of the tumour in regional lymph nodes. S908.D2-vp.1 was established from metastatic tumours that developed in the regional lymph nodes of parental S908.D2-bearing mice during therapy. S908.D2-vp.2-or vp.3 cells were sequentially derived in a similar way from S908.D2-vp. 1-or-vp.2-bearing mice respectively, im which complete tumour regression at each primary site was achieved during therapy. These lines acquired resistance to CY and lentinan and also to 5-fluorouracil (5-FU)/5'-deoxy-5-fluorouracil and lentanin. No significant difference in either the sensitivity to 5-FU or 4-deoxycyclophosphamide in vitro or in the susceptibility to immune effector cells was observed between the parental and progressed lines (S908.D2-vp.1--vp.3). There was an increase in the level of prostaglandin E2 (PGE2) in the progressed lines during repeated therapy (parental, 1171 pg ml-1; vp.1, 2199 pg ml-'; vp.2, 5500 pg m 1-1; vp3, 16187 pg ml-'). There was no significant increase in the production of transforming growth factor ,B (TGF-,B). The amount of interleukin-2 (IL-2) produced by spleen cells isolated from the S908.D2-vp.2-bearing mice was decreased compared with the amount produced by the parental S908.D2-bearing mice. Furthermore, combination therapy with lentinan and IL-2 achieved complete tumour regression in all the mice transplanted with S908.D2 progressed tumour lines, although IL-2 alone did not show any anti-tumour effects in either the S908.D2 parental or progressed lines. The findings suggest that the reduced production of IL-2 induced an increase in the production of the PGE2 by progressed tumour lines is involved in the acquisition of resistance.
The genetic instability and heterogeneity of tumour cells are among the most serious obstacles in the treatment of cancer patients. Multiple genomic changes in tumour cells are not only required for the full development of tumour phenotyes but also for the progression of tumours, including the acquisition of metastatic traits and resistance to therapeutic treatments (Vogelstein et al., 1989; Hunter, 1991; Chang and Loeb, 1993) . It has been suggested that oxygen radicals produced by carcinogenic substances and radiation are involved in the acquisition of genetic instability (Zimmarman and Cerutti, 1984; Turver and Brown, 1987; Ward, 1988) . Recent studies have shown that anti-cancer drugs themselves can induce tumour progression even as they work to destroy tumour cells (McMillan and Hart, 1987; Imamura et al., 1990) . The resistance to chemotherapeutic agents caused by genetic changes in tumour cells is one of the factors involved in tumour progression (Goldie and Coldman, 1979) . Studies to elucidate the mechanisms underlying the acquisition of resistance to drugs have revealed that many genes, such as MDRI and GST-7r, are involved in this process (Kramer et al., 1988; Bradly et al., 1988; Gottesman 1988 . Genetic changes in tumour cells can also result in the escape of tumour cells from surveillance by host immune system (Johnson et al., 1989; Tanaka and Tevethia, 1988; Doherty et al., 1984) . Such genetic changes include the loss of target proteins (tumour-associated antigens), which are usually recognised by antibodies or cytotoxic T lymphocytes (CTLs) , from the surface of tumour cells, and a decrease in the expression of major histocompatibility complex (MHC) class I antigens on tumour cells (Doherty et al., 1984; Tanaka and Tevethia, 1988) .
Recently, many attempts to improve the therapeutic efficacy of anti-cancer drugs have combined the use of chemotherapeutic and immunotherapeutic agents (chemoimmunotherapy). Synergistic effects resulting from such a combination of treatments have been demonstrated in experimental models and in clinics (Paciucci et al., 1989; Mitchell, 1992) . We have also observed synergistic antitumour effects against an established murine fibrosarcoma after treatments with chemotherapeutic agents and an antitumour polysaccharide, lentinan (Suzuki et al., 1994) . Lentinan is a true biological response modifier in the sense that it lacks direct cytotoxic effects against tumour cells and is used in combination with tegafur for the clinical treatment of gastric cancer patients in Japan (Taguchi et al., 1985) . It is not known whether the acquisition of resistance to therapy occurs during chemoimmunotherapy, or whether the mechanisms underlying the acquisition of resistance are distinct from those induced by chemotherapeutic agents or immune effector cells alone.
In this paper we demonstrate that the acquisition of resistance to therapy does occur during chemoimmunotherapy using cyclophosphamide (CY) and lentinan in a murine fibrosarcoma system. The possible mechansims that lead to resistance to chemoimmunotherapy were also investigated.
Materials and methods
Mice BIO.D2 mice were purchased from Shizuoka Laboratory Animal Center (Shizuoka, Japan). The mice were maintained in specific pathogen-free conditions. Normal female mice, 6-10 weeks of age, were used for the experiments.
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vitro in RPMI-1640 medium that was supplemented with 5% fetal bovine serum (FBS Characterisation of the progressed lines in comparison with the parental line The growth rates in vitro and in vivo of the progressed lines were compared with the growth rates of the parental line. No increase in the in vivo growth rate was observed in the progressed lines (data not shown). The rate of growth in vivo of the progressed lines was slightly less than that of the parental line (data not shown).
We investigated whether the acquired resistance of the progressed lines to the combination therapy of lentinan and CY was due to a decreased sensitivity to CY. S908.D2-vp.3 also acquired resistance to the combination of 5-FU/lentinan and 5'-DFUR/lentinan (data not shown and Table III ). There was no difference between the parental line and progressed lines in their sensitivity in vitro to 5-FU or 4-deoxy-cyclophosphamide, which is the active form of CY (Figure 1) . Furthermore, lentinan did not affect the in vitro growth of either the parental or progressed lines (data not shown).
To determine whether the acquired resistance of the progressed lines to chemoimmunotherapy was due to a decrease in the susceptibility of tumour cells to immune effector cells, the susceptibility of S908.D2 lines to CTLs, NK cells, LAK cells or activated macrophages was examined. As shown in Table IV , CTLs raised against an S908.D2 parental line were equally cytotoxic against S908.D2 parental and progressed lines. NK cells and LAK cells were induced from B10.D2 spleen cells by culture with 100 Mg ml-' poly I:C or with 250 u ml-' human rIL-2 respectively. S908.D2 parental and progressed lines were both relatively resistant to poly I:C-activated NK cells and no significant differences in susceptibility were observed between parental and progressed lines (Table IV) . In contrast, both lines were highly sensitive to LAK cells. Again, no significant differences in susceptibility to LAK cells were observed (Table IV) . Activated macrophages were induced from BlO.D2 peritoneal cells by culture with 100 u ml-' murine IFN-y. No significant differences in susceptibility of these lines to activated macrophages were observed (Table IV) .
The parental lines also expressed relatively high levels of class I H-2 antigens (H-2Kd and H-2 Dd), and no reduction in the expression of H-2 antigens was observed in progressed lines (data not shown).
PGE2 and TGF-f production in S908.D2 parental and the progressed lines The results shown in Table IV ' The amount of TGF-,B (pg ml-l) in the medium was measured by a bioassay using MvlLu.
The amount of PGE2 (pg ml-') in the medium was measured by an enzyme immunoassay kit. 'The statistical significance of the differences of TGF-,B and PGE2 production between cell lines was evaluated by the Kruskal-Wallis test. 469 production of immunosuppressive factor(s). The production of TGF-,B and PGE2, the immunosuppressive factors known to be produced by tumour cells (Ceuppens and Goodwin, 1981; Kehrl et al., 1986) , was examined in S908.D2 parental and progressed lines. No significant increase in the production of TGF-,B was observed among these lines (Table V) . In contrast, the levels of PGE2 in progressed lines increased relative to levels in the parental line during repeated chemoimmunotherapy (P<0.05 by the KruskalWallis test). The parental line produced relatively low levels of PGE2 (Table V) . Elevated levels of PGE2 were not observed in S908.D2-nt.1 (1500 pg ml-'), -nt.2 (300 pg ml-') or -nt.3 (1500 pg ml-'). Effects of combination therapy with lentinan and IL-2 on progressed lines Defects in IL-2/IL-2 receptor systems are considered one of the mechanisms of immunosuppression caused by PGE2 (Krause and Deutsch, 1991; Rappaport and Dodge, 1982; Parhar and Lala, 1987) . To determine whether an increase in the production of PGE2 in the progressed lines could result in defects in IL-2/IL-2 receptor systems, the amount of IL-2 present in culture supernatants after mixed lymphocyte tumour cultures (MLTCs) was determined using spleen cells from S908.D2 parental-or S908.D2-vp.2-bearing mice. The amount of IL-2 in supernatants from MLTCs using spleen b cells from S908.D2-vp.2-bearing mice was significantly less compared with that from S908.D2 parental-bearing mice (parental; 29.8 u ml-' vs vp.2; 6.3 u ml-'). To compensate for the decrease in IL-2 levels caused by the overproduction of PGE2, the parental and progressed lines were treated with lentinan and IL-2. The results shown in Figure 2 demonstrate that this combination is fully effective for the S908.D2 parental line (data not shown) as well as the S908.D2-vp.2 line, resulting in a complete cure. IL-2 alone did not produce any significant anti-tumour effects in either S908.D2-vp.2 (Figure 2 ) or S908.D2 parental lines (data not shown). These results suggest that the augmented production of PGE2 in progressed lines results in the acquisition of resistance to chemoimmunotherapy that consists of CY/5-FU/5'-DFUR and lentinan.
Disussion
Many studies have speculated on the mechanisms involved in the acquisition of resistance to chemotherapeutic agents by tumour cells (Schimke, 1984; Bradly et al., 1988; Gottesman, 1988; Kramer et al., 1988) . These studies reveal at least two types of drug resistance; one is quite specific for a selected agent, such as an increase in the amount of dihydrofolate reductase in methotrexate-selected cells, and the other is less specific to selecting agents, such as an increase in the level of P-glycoprotein (Schimke, 1984; Gottesman, 1988) . The resistance observed in our system is distinct from the inherent resistance against selected chemotherapeutic agents because the progressed lines were developed during therapy with CY and lentinan and subsequently acquired resistance to therapy with 5-FU/5'-DFUR and lentinan (Table III and data not shown). Furthermore, the resistance is believed to be distinct from multidrug resistance, such as the increase in the level of P-glycoprotein, because sensitivity in vitro of the S908.D2 parental and S908.D2 vp. 1-3 progressed lines to both 5-FU and 4-deoxycyclophosphamide did not change (Figure 1) .
Several studies have shown that the loss of tumourassociated antigens and a decrease in the expression of MHC class I antigens on tumour cells results in the escape of tumour cells from surveillance by host immune cells (Doherty et al., 1984; Tanaka and Tevethia, 1988 (Ceuppens and Goodwin, 1981; Kehrl et al., 1986) . TGF-# and PGE2 are the immunosuppressive factor(s) indicated so far (Ceuppens and Goodwin, 1981; Kehrl et al., 1986; Li et al., 1993) . In the present study using an S908.D2 murine fibrosarcoma, TGF-# does not appear to be involved in the acquired resistance of the mice to therapeutic drugs (Table  V) . We do demonstrate, however, that PGE2 production in the tumour cells increases gradually during repeated therapy (Table V) . It is well known that PGE2 inhibits both IL-2 production and IL-2 receptor expression on T cells (Krause and Deutsch, 1991; Rappaport and Dodge, 1982; Parhar and Lala, 1987) . Furthermore, recent studies revealed that PGE2 favours a Th2-type of immune response by inhibiting the production of IFN-y by Thl T cells (Phipps et al., 1991) . These findings suggest that the defect in the IL-2/IL-2 receptor system is a possible mechanism for the acquired resistance of progressed lines to chemoimmunotherapy. The production of IL-2 by spleen cells from S908.D2-vp.2-bearing mice was markedly decreased compared with that from the parental S908.D2-bearing mice. Previous studies from our laboratories have shown that lentinan is able to augment the responsiveness of immune effector cells to IL-2 but that lentinan did not augment the production of IL-2 (Hamuro and Chihara, 1985) . Therefore, it may be possible to restore the depressed responsiveness to IL-2 by the application of lentinan in vivo and to compensate for the reduced production of IL-2 by the exogenous infusion of IL-2. The combination therapy of lentinan and IL-2 was completely effective against S908.D2-vp.2 (Figure 2 ). These data suggest that the increased production of PGE2 and the resulting reduced production of IL-2 may be involved in the acquisition of resistance to chemoimmunotherapy in the progressed S908.D2 lines, although we cannot exclude the participation of TGF-1 or other soluble factors in different model systems. Several mechanisms may be responsible for the augmented production of PGE2 from progressed lines. Tumour cells that produce high amounts of PGE2 have been reported to have an increase in metastatic properties relative to tumour cells that produce less PGE2 (Mahan et al., 1985) . Since S908.D2-vp. 1 to vp.3 (progressed tumour lines) were established from metastatic cells in the lymph node, clones producing increased levels of PGE2 might have been selected for. This possibility may be excluded, however, because metastatic lines (S908.D2-nt. 1, -nt.2 or -nt.3) from the lymph nodes of mice that did not received therapy did not acquire resistance to the same chemoimmunotherapy and did not show enhanced PGE2 production. Another possibility is that chemoimmunotherapy itself increases the production of PGE2 in tumour cells. Since the anti-tumour effects of chemoimmunotherapy with CY and lentinan are T cell dependent (M Suzuki et al., unpublished results), host inflammatory cells may be involved in the tumour disruption process. Recent reports demonstrated that oxygen radicals produced by host inflammatory cells induced the augmentation of PGE2 production by tumour cells and that the enhanced production of PGE2 from tumour cells is closely related to the phenotype changes of tumour cells from benign to malignant (Okada et al., 1990 (Okada et al., , 1992 (Okada et al., , 1994 . The elucidation of exact mechanisms for the increased production of PGE2 during therapy requires further detailed studies. In summary, the results presented here highlight the importance of elucidating the biochemical pathways leading to augmented PGE2 production during chemoimmunotherapy in order to understand the mechanisms of tumour progression.
The findings described in this paper demonstrate that tumour cell progression is also induced in chemoimmunotherapy, as it is in chemotherapy. The elucidation of the regulatory mechanisms of tumour cell progression in vivo during chemoimmunotherapy may result in new methods for the treatment of cancer patients, such as combination therapy with lentinan and IL-2.
